Funding

1) Yscript - Yeast cell factory for mRNA bioproduction - Grant Agreement No 101047214, European Union’s Horizon Europe Research and Innovation Programme, do European Innovation Council (EIC) (200 826,70€) – Principal Investigator at UBI Fani Sousa; Consortium:CNRS (France), INRAE (France), TRON gGmbH (Germany), IBCH PAS (Poland),UAVR (Portugal) UBI (Portugal), BIA Sep (Slovenia), EURICE (Germany).

2) WASTESILK: Silk Sericin as an industrial wastewater with valuable biomedical potential PTDC/BTA-BTA/0696/2020, Total: 249.965,65€, Principal Investigator: Maximiano Ribeiro.

3) PAPILOMA: Vaginal gel for topical application in precancerous lesions caused by the Human Papilloma Virus ref. CENTRO-01-0145-FEDER-181235, (150 000€) - Principal Investigator: Carla Cruz (Ongoing); Co-promotor: HPRD – Health Products Research and Development Lda; Partners: UTAD-CITAB, CHUCB.

4) GRAPHY funded in FCT Call for R&D Projects in All Scientific Domains 2022 entitled “Thiol-ene click injectable in situ forming hydrogels incorporating graphene: optimization of the polymer-related features for the immuno-photothermal therapy of metastatic breast cancer” – Principal Investigator: Duarte Diogo; Co-Investigator: António Mendonça; Partners: Ricardo O. Louro, ITQB-UNL, Sandra Pucciarelli, UNICAM; Total funding awarded: 49944,60 €, Ref.: 2022.06320.PTDC.

5) European Projects as Senior Researcher ENTRANCE - “Enhancing the ENTRepreneurial mindset of non-business Academics in Europe”, Project number 2020-1-CY01-KA203-065982, Co-funded by the Erasmus+ Program of the European Union, 2020-2022 (24 months). Total Budget: 63 k €; UBI Budget: 298,6 k€. Ana Cristina Cabral is team member.

6) Ignition Projects and Proofs of Concept within the scope of the INOVC+ project, “DEFEND”: Vaginal gel for cancerous lesions caused by the Human Papilloma Virus”. Principal Investigator: Carla Cruz (6 150€).

7) Ignition Projects and Proofs of Concept within the scope of the INOVC+ project, “NanoINTer: Functionalized DNA Nanovaccine for Cervical Cancer Immunotherapy”, Principal Investigator: Ângela Sousa (6 150€).

8) ZAPGO: “Zwitterionic-based amphiphile coated Graphene Oxide nanostructures for chemophotothermal therapy of breast cancer ”, approved for funding in Call 02/SAICT/2017 ref. CENTRO-01-0145-FEDER-028989- Scientific Research and Technological Development (IC&DT) projects, April 2018 - April 2022; Principal Investigator: Ilídio J. Correia; Total funding: 237.603,03 €, UBI: 169.995,89 €, PRODEQ e IPG; Co-PI: Paula Ferreira, CIEPQPF.

9) InEye: “Non-invasive ocular insert for drug delivery”, approved for funding in Call 02/SAICT/2017 ref. POCI-01-0145-FEDER-031462– Scientific Research and Technological Development (IC&DT) projects, July 2018 – July 2022. Total funding: 223.441,50 €, UBI: 37.555,73 €, Principal Investigator: Paula Ferreira, PRODEQ, Co- Investigator: Ilídio J. Correia.

10) PUREmiRSILs: Ionic Liquid-based supports for pre-miRNAs purification targeting Alzheimer's disease. POCI-01-0145-FEDER-029496, Principal Investigator: Fani Sousa; Total funding: 239 607€.

CICS-UBI - Centro de Investigação em Ciências da Saúde
[Health Sciences Research Center]
Faculdade de Ciências da Saúde
Av. Infante D. Henrique | 6201-506 Covilhã | Portugal

Tel.: 275 329 002/3 — Fax: 275 329 099
(Calls made to the phone numbers in this page will be charged as a Portuguese nacional call.)
Email: cics@fcsaude.ubi.pt
GPS: N 40°16'6.33" W 7°29'39.13" (40.268425; -7.494202)

Follow CICS on: